Evidence map›Paper›PMID 40216720›Full record

ArticleDoklady. Biochemistry and biophysics2025

Modular Nanotransporters Containing Keap1 Monobodies Are Capable of Reducing the Toxic Effect of Acetaminophen on the Liver of Mice.

Yu V Khramtsov, A A Rosenkranz, A V Ulasov, T A Slastnikova, T N Lupanova, R T Alieva, G P Georgiev, A S Sobolev

Abstract read
PubMed Publisher
In one paragraph

Article in Doklady. Biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yu V KhramtsovInstitute of Gene Biology, Russian Academy of Sciences, Moscow, Russia.
A A RosenkranzInstitute of Gene Biology, Russian Academy of Sciences, Moscow, Russia.
A V UlasovInstitute of Gene Biology, Russian Academy of Sciences, Moscow, Russia.
T A SlastnikovaInstitute of Gene Biology, Russian Academy of Sciences, Moscow, Russia.
T N LupanovaInstitute of Gene Biology, Russian Academy of Sciences, Moscow, Russia.
R T AlievaInstitute of Gene Biology, Russian Academy of Sciences, Moscow, Russia.
G P GeorgievInstitute of Gene Biology, Russian Academy of Sciences, Moscow, Russia.
A S SobolevInstitute of Gene Biology, Russian Academy of Sciences, Moscow, Russia. alsobolev@yandex.ru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previously, we created a modular nanotransporter (MNT) containing a monobody to Keap1, an intracellular protein inhibitor of the Nrf2 transcription factor that controls cellular protection from oxidative stress and is capable of interacting with Keap1 in hepatocytes and protect these cells from the effects of hydrogen peroxide. Oxidative liver damage by acetaminophen was used as a model to study the antitoxic effect of this MNT. Intraperitoneal injection of acetaminophen to mice resulted in an increase in the level of alanine aminotransferase and aspartate aminotransferase in the blood, as well as in liver edema. A significant decrease in the level of these enzymes in the blood, along with a decrease in liver edema, was observed after preliminary intravenous administration of MNT 2 h before the acetaminophen injection. The results obtained can be used as a basis for developing drugs to treat diseases associated with oxidative stress.

Indexed as

AcetaminophenChemical and Drug Induced Liver InjuryKelch-Like ECH-Associated Protein 1LiverAnimalsMaleMiceOxidative StressAcetaminophenKeap1 protein, mouseKelch-Like ECH-Associated Protein 1acetaminophenALTASTKeap1modular nanotransportersmonobodiesNrf2single-photon emission computed tomography

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.